DBD is expected to report earnings to rise 83.58% to $1.23 per share on August 12
Q2'26
Est.
$1.23
Q1'26
Beat
by $0.05
Q4'25
Beat
by $1.30
Q3'25
Beat
by $0.28
Q2'25
Missed
by $0.01
The last earnings report on April 30 showed earnings per share of 67 cents, beating the estimate of 62 cents. With 443.00K shares outstanding, the current market capitalization sits at 2.83B.
A.I.dvisor indicates that over the last year, DBD has been loosely correlated with GDRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DBD jumps, then GDRX could also see price increases.
DBD in +1.15% Uptrend, growing for three consecutive days on June 12, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DBD advanced for three days, in of 199 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DBD's RSI Indicator exited the oversold zone, of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 26, 2026. You may want to consider a long position or call options on DBD as a result. In of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for DBD just turned positive on May 26, 2026. Looking at past instances where DBD's MACD turned positive, the stock continued to rise in of 28 cases over the following month. The odds of a continued upward trend are .
DBD moved above its 50-day moving average on May 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DBD crossed bullishly above the 50-day moving average on June 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
DBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 40 cases where DBD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for DBD entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DBD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.766) is normal, around the industry mean (25.631). P/E Ratio (28.179) is within average values for comparable stocks, (75.382). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.572). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (0.778) is also within normal values, averaging (51.954).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
